{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:57:45Z","timestamp":1775091465658,"version":"3.50.1"},"reference-count":43,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/BIAMOL\/31787\/2017"],"award-info":[{"award-number":["PTDC\/BIAMOL\/31787\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["UID\/MULTI\/04046\/2019"],"award-info":[{"award-number":["UID\/MULTI\/04046\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["PD\/BD\/114388\/2016"],"award-info":[{"award-number":["PD\/BD\/114388\/2016"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sociedade Portuguesa de Endocrinologia\/Merck","award":["Bolsa Edward Limbert Merck\/SPEDM -2021"],"award-info":[{"award-number":["Bolsa Edward Limbert Merck\/SPEDM -2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The Sodium\/Iodide Symporter (NIS) is responsible for the active transport of iodide into thyroid follicular cells. Differentiated thyroid carcinomas (DTCs) usually preserve the functional expression of NIS, allowing the use of radioactive iodine (RAI) as the treatment of choice for metastatic disease. However, a significant proportion of patients with advanced forms of TC become refractory to RAI therapy and no effective therapeutic alternatives are available. Impaired iodide uptake is mainly caused by the defective functional expression of NIS, and this has been associated with several pathways linked to malignant transformation. MAPK signaling has emerged as one of the main pathways implicated in thyroid tumorigenesis, and its overactivation has been associated with the downregulation of NIS expression. Thus, several strategies have been developed to target the MAPK pathway attempting to increase iodide uptake in refractory DTC. However, MAPK inhibitors have had only partial success in restoring NIS expression and, in most cases, it remained insufficient to allow effective treatment with RAI. In a previous work, we have shown that the activity of the small GTPase RAC1 has a positive impact on TSH-induced NIS expression and iodide uptake in thyroid cells. RAC1 is a downstream effector of NRAS, but not of BRAF. Therefore, we hypothesized that the positive regulation induced by RAC1 on NIS could be a relevant signaling cue in the mechanism underlying the differential response to MEK inhibitors, observed between NRAS- and BRAF-mutant tumors. In the present study, we found that the recovery of NIS expression induced through MAPK pathway inhibition can be enhanced by potentiating RAC1 activity in thyroid cell systems. The negative impact on NIS expression induced by the MAPK-activating alterations, NRAS Q61R and BRAF V600E, was partially reversed by the presence of the MEK 1\/2 inhibitors AZD6244 and CH5126766. Notably, the inhibition of RAC1 signaling partially blocked the positive impact of MEK inhibition on NIS expression in NRAS Q61R cells. Conversely, the presence of active RAC1 considerably improved the rescue of NIS expression in BRAF V600E thyroid cells treated with MEK inhibitors. Overall, our data support an important role for RAC1 signaling in enhancing MAPK inhibition in the context of RAI therapy in DTC, opening new opportunities for therapeutic intervention.<\/jats:p>","DOI":"10.3390\/cancers13225861","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T02:55:17Z","timestamp":1637636117000},"page":"5861","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6601-1138","authenticated-orcid":false,"given":"M\u00e1rcia","family":"Faria","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Endocrinologia, Diabetes e Metabolismo, do Centro Hospitalar Universit\u00e1rio de Lisboa Norte-Hospital Santa Maria, 1649-035 Lisboa, Portugal"},{"name":"BioISI-Biosystems and Integrative Sciences Institute, Faculdade de Ci\u00eancias da Universidade de Lisboa, 1749-016 Lisboa, Portugal"},{"name":"Departamento de Gen\u00e9tica Humana, Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge, 1649-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-3795","authenticated-orcid":false,"given":"Rita","family":"Domingues","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Endocrinologia, Diabetes e Metabolismo, do Centro Hospitalar Universit\u00e1rio de Lisboa Norte-Hospital Santa Maria, 1649-035 Lisboa, Portugal"},{"name":"ISAMB-Instituto de Sa\u00fade Ambiental, Faculty of Medicine, University of Lisbon, 1649-035 Lisboa, Portugal"},{"name":"Faculty of Medicine, University of Lisbon, 1649-035 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-7350","authenticated-orcid":false,"given":"Maria Jo\u00e3o","family":"Bugalho","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Endocrinologia, Diabetes e Metabolismo, do Centro Hospitalar Universit\u00e1rio de Lisboa Norte-Hospital Santa Maria, 1649-035 Lisboa, Portugal"},{"name":"Faculty of Medicine, University of Lisbon, 1649-035 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9379-9696","authenticated-orcid":false,"given":"Paulo","family":"Matos","sequence":"additional","affiliation":[{"name":"BioISI-Biosystems and Integrative Sciences Institute, Faculdade de Ci\u00eancias da Universidade de Lisboa, 1749-016 Lisboa, Portugal"},{"name":"Departamento de Gen\u00e9tica Humana, Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge, 1649-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4839-8279","authenticated-orcid":false,"given":"Ana Lu\u00edsa","family":"Silva","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Endocrinologia, Diabetes e Metabolismo, do Centro Hospitalar Universit\u00e1rio de Lisboa Norte-Hospital Santa Maria, 1649-035 Lisboa, Portugal"},{"name":"ISAMB-Instituto de Sa\u00fade Ambiental, Faculty of Medicine, University of Lisbon, 1649-035 Lisboa, Portugal"},{"name":"Faculty of Medicine, University of Lisbon, 1649-035 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-physiol-022516-034125","article-title":"The Sodium\/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications","volume":"79","author":"Ravera","year":"2017","journal-title":"Annu. Rev. Physiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/thy.2006.16.109","article-title":"Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer","volume":"16","author":"Cooper","year":"2006","journal-title":"Thyroid"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pharmthera.2012.06.007","article-title":"The Sodium Iodide Symporter (NIS): Regulation and Approaches to Targeting for Cancer Therapeutics","volume":"135","author":"Kogai","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1210\/me.2002-0109","article-title":"A Thyroid-Specific Far-Upstream Enhancer in the Human Sodium\/Iodide Symporter Gene Requires Pax-8 Binding and Cyclic Adenosine 3\u2032,5\u2032-Monophosphate Response Element-like Sequence Binding Proteins for Full Activity and Is Differentially Regulated in Normal and Thyroid Cancer Cells","volume":"16","author":"Taki","year":"2002","journal-title":"Mol. Endocrinol."},{"key":"ref_5","first-page":"121","article-title":"Different Expression of TSH Receptor and NIS Genes in Thyroid Cancer: Role of Epigenetics","volume":"52","author":"Sponziello","year":"2014","journal-title":"J. Mol. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12672-014-0203-0","article-title":"Modulation of Sodium Iodide Symporter in Thyroid Cancer","volume":"5","author":"Lakshmanan","year":"2014","journal-title":"Horm Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s12022-011-9170-y","article-title":"Molecular Analysis of Thyroid Tumors","volume":"22","author":"Bhaijee","year":"2011","journal-title":"Endocr. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3892\/ijo.2012.1681","article-title":"Signaling Pathways in Follicular Cell-Derived Thyroid Carcinomas (Review)","volume":"42","author":"Romitti","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1210\/jc.2009-1888","article-title":"Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways","volume":"95","author":"Hou","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","article-title":"Molecular Genetics and Diagnosis of Thyroid Cancer","volume":"7","author":"Nikiforov","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_11","first-page":"1454","article-title":"High Prevalence of BRAF Mutations in Thyroid Cancer: Genetic Evidence for Constitutive Activation of the RET\/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Carcinoma","volume":"63","author":"Kimura","year":"2003","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF Gene in Human Cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-15-0254","article-title":"BRAF V600E and Decreased NIS and TPO Expression Are Associated with Aggressiveness of a Subgroup of Papillary Thyroid Microcarcinoma","volume":"173","author":"Bastos","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1530\/EC-17-0302","article-title":"NIS Expression in Thyroid Tumors, Relation with Prognosis Clinicopathological and Molecular Features","volume":"7","author":"Tavares","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1677\/erc.1.01119","article-title":"The Oncogene BRAFV600E Is Associated with a High Risk of Recurrence and Less Differentiated Papillary Thyroid Carcinoma Due to the Impairment of Na+\/I\u2212 Targeting to the Membrane","volume":"13","author":"Nistal","year":"2006","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1210\/jc.2006-2707","article-title":"BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism","volume":"92","author":"Durante","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Romei, C., Ciampi, R., Faviana, P., Agate, L., Molinaro, E., Bottici, V., Basolo, F., Miccoli, P., Pacini, F., and Pinchera, A. (2020, April 22). BRAFV600E Mutation, but Not RET\/PTC Rearrangements, Is Correlated with a Lower Expression of Both Thyroperoxidase and Sodium Iodide Symporter Genes in Papillary Thyroid Cancer in: Endocrine-Related Cancer Volume 15 Issue 2. Available online: https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/15\/2\/511.xml.","DOI":"10.1677\/ERC-07-0130"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2265.2008.03376.x","article-title":"Expression of Iodine Metabolism Genes in Human Thyroid Tissues: Evidence for Age and BRAFV600E Mutation Dependency","volume":"70","author":"Espadinha","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.anndiagpath.2016.04.002","article-title":"The Correlation of Sodium Iodide Symporter and BRAFV600E Mutation in Classical Variant Papillary Thyroid Carcinoma","volume":"22","author":"Yazgan","year":"2016","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.critrevonc.2014.08.007","article-title":"The Evolving Field of Kinase Inhibitors in Thyroid Cancer","volume":"93","author":"Marotta","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19843","DOI":"10.18632\/oncotarget.15773","article-title":"HER Inhibitor Promotes BRAF\/MEK Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Harboring BRAFV600E","volume":"8","author":"Cheng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1089\/thy.2019.0143","article-title":"Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol","volume":"29","author":"Iravani","year":"2019","journal-title":"Thyroid"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.surg.2019.04.076","article-title":"Dual Inhibition of BRAF and MEK Increases Expression of Sodium Iodide Symporter in Patient-Derived Papillary Thyroid Cancer Cells in Vitro","volume":"167","author":"Ullmann","year":"2020","journal-title":"Surgery"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.omto.2019.01.007","article-title":"MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF V600E: An In Vitro Study","volume":"12","author":"Fu","year":"2019","journal-title":"Mol. Oncolytics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1172\/JCI46382","article-title":"Small-Molecule MAPK Inhibitors Restore Radioiodine Incorporation in Mouse Thyroid Cancers with Conditional BRAF Activation","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrm2476","article-title":"Mammalian Rho GTPases: New Insights into Their Functions from in Vivo Studies","volume":"9","author":"Heasman","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1158\/1541-7786.MCR-08-0542","article-title":"Oncogenic Ras Signals through Activation of Both Phosphoinositide 3-Kinase and Rac1 to Induce c-Jun NH2-Terminal Kinase\u2013Mediated, Caspase-Independent Cell Death","volume":"7","author":"Byun","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/jid.2012.186","article-title":"Activated Mutant NRasQ61K Drives Aberrant Melanocyte Signaling, Survival, and Invasiveness via a Rac1-Dependent Mechanism","volume":"132","author":"Li","year":"2012","journal-title":"J. Investig. Derm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cellsig.2018.01.004","article-title":"Oncogenic RAC1 and NRAS Drive Resistance to Endoplasmic Reticulum Stress through MEK\/ERK Signalling","volume":"44","author":"Bright","year":"2018","journal-title":"Cell Signal"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/JME-19-0195","article-title":"Antagonistic Effects of RAC1 and Tumor-Related RAC1b on NIS Expression in Thyroid","volume":"63","author":"Faria","year":"2019","journal-title":"J. Mol. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Faria, M., Domingues, R., Bugalho, M.J., Silva, A.L., and Matos, P. (2021). Analysis of NIS Plasma Membrane Interactors Discloses Key Regulation by a SRC\/RAC1\/PAK1\/PIP5K\/EZRIN Pathway with Potential Implications for Radioiodine Re-Sensitization Therapy in Thyroid Cancer. Cancers, 13.","DOI":"10.3390\/cancers13215460"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"50442","DOI":"10.1074\/jbc.M308215200","article-title":"Tumor-Related Alternatively Spliced Rac1b Is Not Regulated by Rho-GDP Dissociation Inhibitors and Exhibits Selective Downstream Signaling","volume":"278","author":"Matos","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"38788","DOI":"10.1038\/srep38788","article-title":"Intermolecular Interactions in the TMEM16A Dimer Controlling Channel Activity","volume":"6","author":"Scudieri","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1158\/0008-5472.CAN-12-3937","article-title":"Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity","volume":"73","author":"Ishii","year":"2013","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13026","DOI":"10.1038\/s41598-018-31514-2","article-title":"Prolonged Co-Treatment with HGF Sustains Epithelial Integrity and Improves Pharmacological Rescue of Phe508del-CFTR","volume":"8","author":"Matos","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Faria, M., Matos, P., Pereira, T., Cabrera, R., Cardoso, B.A., Bugalho, M.J., and Silva, A.L. (2017). RAC1b Overexpression Stimulates Proliferation and NF-KB-Mediated Anti-Apoptotic Signaling in Thyroid Cancer Cells. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172689"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.7150\/thno.57689","article-title":"Molecular Mechanisms of Radioactive Iodine Refractoriness in Differentiated Thyroid Cancer: Impaired Sodium Iodide Symporter (NIS) Expression Owing to Altered Signaling Pathway Activity and Intracellular Localization of NIS","volume":"11","author":"Oh","year":"2021","journal-title":"Theranostics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-09-3064","article-title":"Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response","volume":"16","author":"Pratilas","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","article-title":"Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer","volume":"149","author":"Duncan","year":"2012","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1172\/JCI89067","article-title":"Sustained ERK Inhibition Maximizes Responses of BrafV600E Thyroid Cancers to Radioiodine","volume":"126","author":"Nagarajah","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.bbrc.2017.09.125","article-title":"Immunohistochemical Evalulation of Activated Ras and Rac1 as Potential Downstream Effectors of Aquaporin-5 in Breast Cancer in Vivo","volume":"493","author":"Jensen","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/22\/5861\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:34:02Z","timestamp":1760168042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/22\/5861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":43,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cancers13225861"],"URL":"https:\/\/doi.org\/10.3390\/cancers13225861","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]}}}